Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
Status:
Terminated
Trial end date:
2020-03-10
Target enrollment:
Participant gender:
Summary
This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability,
pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant
ruxolitinib. The first part (Dose Escalation) will employ a standard 3+3 dose escalation
design to determine Maximum Tolerated Dose (MTD). The second part of the study (Dose
Confirmation) will confirm the recommended Phase 2 dose (RP2D) in an expanded population.